ClinicalTrials.gg
TerminatedNCT03669640Updated Aug 12, 2024Results posted

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

A Phase 2 interventional study of RO6889450 and Placebo in Schizophrenia, Schizoaffective Disorder, sponsored by Hoffmann-La Roche. Terminated at 45 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
This study was discontinued due to an interim analysis which indicated that ralmitaront was unlikely to meet its primary endpoint.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
11th of 16
131 · median 294
Started
2018
with 1 other
Phase 2
5 of 19
none open now
Registered
17th of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 17th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

03

Conditions studied

  • Schizophrenia, Schizoaffective Disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a (DSM-5) diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or pure D2 antagonist(s), or a D2 partial agonist for a minimum of 6 months and receiving no more than two antipsychotics
  • Medically stable during the 3 months prior to study entry
  • Participant is an outpatient with no psychiatric hospitalizations within the prior 6 months
  • PANSS negative symptom factor score of 18 or higher
  • The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness), P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6 (suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse control)
  • Has an informant who is considered reliable by the Investigator
  • (BMI) between 18-40 kg/m2 inclusive
  • Female participants are eligible to participate if not pregnant, not breastfeeding and agree to remain abstinent or use acceptable methods during the treatment period and for at least 28 days after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Moderate to severe substance use disorder within six months of study entry (excluding nicotine or caffeine) as defined by
  • Extrapyramidal symptom rating scale (ESRS-A CGI) subscore greater than or equal to 3
  • Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)
  • PANSS item G6 (depression) greater than or equal to 5
  • Significant risk of suicide or harming him- or herself or others according to the Investigator's judgment
  • A prior or current general medical condition that might be impairing cognition or other psychiatric functioning
  • Positive result at screening for surface antigen (HBsAg), (HCV), or -1 and HIV-2. HCV antibody positive participants are eligible if HCV RNA is negative
  • Tardive dyskinesia that is moderate to severe or requires treatment
  • History of neuroleptic malignant syndrome
  • Average triplicate Fridericia's Correction Formula () interval greater than 450 milliseconds (msec) for males and 470 msec for females or other abnormality on screening (ECG) based on centralized reading
  • Clinically significant abnormalities in laboratory safety test results
  • Significant or unstable physical condition that in the investigator's judgment might require a change in medication or hospitalization during the course of the study
  • On more than one antidepressant, or if on one antidepressant, a change in dose within 28 days prior to screening
  • History of clozapine treatment
  • History of treatment with electroconvulsive therapy (ECT)
  • Concomitant use of prohibited medications
  • Positive urine drug screen for amphetamines, methamphetamines, opiates, buprenomorphine, methadone, cannabinoids, cocaine, and barbiturates
  • Receipt of an drug within 28 days or five times the half-life of the investigational drug (whichever is longer) before the first study drug administration
  • Donation of blood over 400 mL within 3 months prior to screening
  • Diagnosis of COVID-19 infection (confirmed or presumptive) 4 weeks prior to screening or during screening. Participants can be re-screened after 4 weeks of full recovery in addition to Investigator and/or institutional approval to enroll
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Part A: Monotherapy

    Participants will receive RO6889450 or a dose-matched placebo. NOTE: Part A has completed enrollment.

    Drug: RO6889450 · Drug: Placebo

  • Experimental
    Part B: Add-On Therapy

    Participants will receive a low or high dose of RO6889450 or a dose-matched placebo in addition to their usual anti-psychotic treatment(s).

    Drug: RO6889450 · Drug: Placebo

Interventions

  • Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.

  • DrugPlacebo

    Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Brief Negative Symptoms Scale (BNSS) Avolition/Apathy Subscore and Total Score at Baseline and Week 12

    The BNSS is a 13-item instrument designed for clinical trials that measures the severity of the negative symptoms of schizophrenia in five domains. There are 13 items organized into 6 subscales (anhedonia, distress, asociality, avolition, blunted affect, and alogia), each rated on a 7-point scale (0-6) where 0 = absent symptoms and 6 = severe symptoms. The total score is calculated by summing the individual items (13) of each subscale and has a range of 0-78. The avolition/apathy subscale contains 2 items with a total score range of 0-12.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Clinical Global Impression Severity (CGI-S) Overall Scores

    The CGI-S is an absolute measure assessing how mentally ill the participant is at the time of the assessment on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). On the scale, the value 0 corresponds to 'not assessed', which will be excluded from the analyses. The values 1 to 7 will be transformed into the 0 to 6 range prior to statistical analysis for the question on the measure ("Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?"), making the total score range 0-6.

    Time frame: Baseline to week 12

  2. CGI-S Negative Symptoms (NS) Scores

    The CGI-S-NS is similar to the CGI-S and is assessed on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). On the scale, the value 0 corresponds to 'not assessed', which will be excluded from the analyses. The values 1 to 7 will be transformed into the 0 to 6 range prior to statistical analysis for the question on the measure, making the total score range 0-6.

    Time frame: Baseline to week 12

  3. Clinical Global Impression - Improvement (CGI-I) Overall Scores

    The CGI-I assesses how much the participant's condition has changed at the time of the assessment in comparison to their condition at baseline. It uses a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), where the value 0 corresponds to 'not assessed' and will be excluded from any analyses.

    Time frame: Up to Week 12 (Day 84)

  4. CGI-I Negative Symptoms Scores

    The CGI-I NS is similar to the CGI-I and assesses how much the participant's condition has changed at the time of the assessment in comparison to their condition at baseline. It uses a 7-point scale, where: 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse

    Time frame: Up to Week 12 (Day 84)

  5. Positive and Negative Syndrome Scale (PANSS) Total Scores

    The PANSS Marder factors examine schizophrenia symptoms in five domains: positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility/excitement, and depression/anxiety. The Marder factor positive symptom score (range = 8-56) measures responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12) while the negative symptom factor score (range = 7-49) consists of 7 items (N1,N2,N3,N4,N6,G7,G16). Each item is scored on a scale of 1-7, where 1 = an absence of symptoms and 7 = extreme symptoms. The positive and negative syndrome scale total score is the sum of the scores from each domain (range = 15-105); higher scores indicate greater severity of symptoms.

    Time frame: Baseline to week 12

  6. PANSS Symptom Factor Scores

    The PANSS Marder factors examine schizophrenia symptoms in five domains: positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility/excitement, and depression/anxiety. The Marder factor positive symptom score (range = 8-56) measures responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12) while the negative symptom factor score (range = 7-49) consists of 7 items (N1,N2,N3,N4,N6,G7,G16). Each item is scored on a scale of 1-7, where 1 = an absence of symptoms and 7 = extreme symptoms.

    Time frame: Baseline to week 12

  7. Brief Negative Symptom Scale (BNSS) Total Scores

    The BNSS is a 13-item instrument designed for clinical trials that measures the severity of the negative symptoms of schizophrenia in five domains. There are 13 items organized into 6 subscales (anhedonia, distress, asociality, avolition, blunted affect, and alogia), each rated on a 7-point scale (0-6) where 0 = absent symptoms and 6 = severe symptoms. The total score is calculated by summing the individual items (13) of each subscale and has a range of 0-78.

    Time frame: Baseline to week 12

  8. Defeatist Performance Attitude Scale (DPAS) Scores

    The DPAS is a 15-item, patient-rated assessment that evaluates expectations of failures or self-defeating beliefs related to prior failed experiences as well as illness on a 7-point Likert scale (total range = 15-105) ranging from totally agree (1) to totally disagree (7).

    Time frame: Baseline to week 12

  9. Number of Participants With Suicidal Ideation or Behavior, and Self-injurious Behavior Without Suicidal Intent on the Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a suicide risk assessment tool used to help identify the risk of suicide.

    Time frame: Baseline through Day 84

  10. Extrapyramidal Symptom Rating Scale, Abbreviated (ESRS-A)

    The ESRS-A is used to evaluate the presence and severity of extrapyramidal symptoms. Items are rated on a scale of 0 (no symptoms) to 5 (extreme symptoms).

    Time frame: Baseline through Day 84

  11. Maximum Serum Concentration (Cmax) of RO6889450

    Time frame: Day 42

  12. Area Under the Curve at Steady State (AUCss) of RO6889450

    Time frame: Day 42

07

Results

Posted Aug 12, 2024

Participant flow

Participant flow — Overall Study
MilestonePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Started15123753032
Completed1073352729
Not completed554033
Withdrew: Study terminated by sponsor000010
Withdrew: Lost to follow-up002000
Withdrew: Death001000
Withdrew: Withdrawal by subject121013
Withdrew: Protocol violation100000
Withdrew: Physician decision020000
Withdrew: Disease relapse100000
Withdrew: Adverse event210010

Outcome measures

PrimaryBrief Negative Symptoms Scale (BNSS) Avolition/Apathy Subscore and Total Score at Baseline and Week 12

The BNSS is a 13-item instrument designed for clinical trials that measures the severity of the negative symptoms of schizophrenia in five domains. There are 13 items organized into 6 subscales (anhedonia, distress, asociality, avolition, blunted affect, and alogia), each rated on a 7-point scale (0-6) where 0 = absent symptoms and 6 = severe symptoms. The total score is calculated by summing the individual items (13) of each subscale and has a range of 0-78. The avolition/apathy subscale contains 2 items with a total score range of 0-12.

Time frame:
Baseline to Week 12
Reported as:
Mean · Units on a scale
Brief Negative Symptoms Scale (BNSS) Avolition/Apathy Subscore and Total Score at Baseline and Week 12
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Baseline Avolition/Apathy Subscore5.71 ± 2.815.50 ± 2.716.0 ± 2.36.2 ± 1.35.8 ± 1.95.9 ± 2.4
Week 12 (Day 84) Avolition/Apathy Subscore5.50 ± 2.554.67 ± 3.275.0 ± 1.95.3 ± 1.04.1 ± 2.14.7 ± 2.1
SecondaryClinical Global Impression Severity (CGI-S) Overall Scores

The CGI-S is an absolute measure assessing how mentally ill the participant is at the time of the assessment on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). On the scale, the value 0 corresponds to 'not assessed', which will be excluded from the analyses. The values 1 to 7 will be transformed into the 0 to 6 range prior to statistical analysis for the question on the measure ("Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?"), making the total score range 0-6.

Time frame:
Baseline to week 12
Reported as:
Mean · Units on a scale
Clinical Global Impression Severity (CGI-S) Overall Scores
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Baseline3.600 ± 0.5073.667 ± 0.4924.1 ± 0.73.8 ± 0.43.9 ± 0.74.0 ± 0.7
Day 143.467 ± 0.5163.700 ± 0.4834.0 ± 0.63.8 ± 0.53.8 ± 0.64.0 ± 0.8
Day 283.500 ± 0.5273.333 ± 0.5003.9 ± 0.83.8 ± 0.53.8 ± 0.63.7 ± 0.7
Day 423.636 ± 0.8093.375 ± 0.7443.8 ± 0.83.8 ± 0.53.6 ± 0.63.6 ± 0.7
Day 563.636 ± 0.5053.143 ± 0.3783.8 ± 0.83.8 ± 0.53.5 ± 0.73.5 ± 0.8
Day 703.500 ± 0.7073.143 ± 0.690————
Day 843.700 ± 0.4833.000 ± 0.6323.7 ± 0.83.8 ± 0.53.4 ± 0.63.5 ± 0.7
SecondaryCGI-S Negative Symptoms (NS) Scores

The CGI-S-NS is similar to the CGI-S and is assessed on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). On the scale, the value 0 corresponds to 'not assessed', which will be excluded from the analyses. The values 1 to 7 will be transformed into the 0 to 6 range prior to statistical analysis for the question on the measure, making the total score range 0-6.

Time frame:
Baseline to week 12
Reported as:
Mean · Units on a scale
CGI-S Negative Symptoms (NS) Scores
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Baseline3.867 ± 0.7433.917 ± 0.6694.4 ± 0.64.2 ± 0.44.3 ± 0.74.3 ± 0.7
Day 143.600 ± 0.6323.800 ± 0.6324.3 ± 0.74.3 ± 0.53.9 ± 0.74.1 ± 0.7
Day 283.800 ± 0.6323.778 ± 0.6674.1 ± 0.84.3 ± 0.53.8 ± 0.73.9 ± 0.7
Day 423.727 ± 0.4673.625 ± 0.5183.9 ± 0.94.0 ± 0.03.8 ± 0.73.7 ± 0.7
Day 563.636 ± 0.6743.714 ± 0.7563.9 ± 0.84.0 ± 0.03.6 ± 0.73.5 ± 0.7
Day 703.500 ± 0.5273.286 ± 0.756————
Day 843.400 ± 0.5163.167 ± 0.7533.9 ± 0.83.8 ± 0.53.4 ± 0.63.5 ± 0.9
SecondaryClinical Global Impression - Improvement (CGI-I) Overall Scores

The CGI-I assesses how much the participant's condition has changed at the time of the assessment in comparison to their condition at baseline. It uses a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), where the value 0 corresponds to 'not assessed' and will be excluded from any analyses.

Time frame:
Up to Week 12 (Day 84)
Reported as:
Mean · Units on a scale
Clinical Global Impression - Improvement (CGI-I) Overall Scores
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Day 143.71 ± 0.913.56 ± 0.533.7 ± 0.44.0 ± 0.03.6 ± 0.53.6 ± 0.6
Day 214.00 ± NA2.00 ± NA————
Day 283.56 ± 0.733.50 ± 0.763.5 ± 0.74.0 ± 0.03.5 ± 0.83.4 ± 0.8
Day 353.50 ± 0.71—————
Day 423.73 ± 0.653.29 ± 0.763.4 ± 0.73.8 ± 0.53.3 ± 0.83.3 ± 0.9
Day 563.70 ± 0.483.14 ± 0.693.4 ± 0.73.8 ± 0.53.4 ± 0.93.1 ± 1.0
Day 703.50 ± 0.712.86 ± 0.90————
Day 843.80 ± 0.423.00 ± 0.633.2 ± 0.73.8 ± 0.53.0 ± 0.93.0 ± 1.0
SecondaryCGI-I Negative Symptoms Scores

The CGI-I NS is similar to the CGI-I and assesses how much the participant's condition has changed at the time of the assessment in comparison to their condition at baseline. It uses a 7-point scale, where: 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse

Time frame:
Up to Week 12 (Day 84)
Reported as:
Mean · Units on a scale
CGI-I Negative Symptoms Scores
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Day 143.71 ± 0.613.44 ± 0.733.7 ± 0.54.0 ± 0.03.5 ± 0.63.5 ± 0.6
Day 215.00 ± NA4.00 ± NA————
Day 283.44 ± 0.733.38 ± 0.743.5 ± 0.74.0 ± 0.03.3 ± 0.73.2 ± 0.8
Day 354.50 ± 0.71—————
Day 423.45 ± 0.693.43 ± 0.793.3 ± 0.63.5 ± 0.63.3 ± 0.83.2 ± 0.8
Day 563.50 ± 0.713.43 ± 0.533.2 ± 0.73.5 ± 0.63.2 ± 0.82.9 ± 0.8
Day 703.40 ± 0.703.00 ± 0.82————
Day 843.10 ± 0.742.83 ± 0.413.1 ± 0.73.0 ± 0.82.9 ± 0.92.8 ± 0.9
SecondaryPositive and Negative Syndrome Scale (PANSS) Total Scores

The PANSS Marder factors examine schizophrenia symptoms in five domains: positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility/excitement, and depression/anxiety. The Marder factor positive symptom score (range = 8-56) measures responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12) while the negative symptom factor score (range = 7-49) consists of 7 items (N1,N2,N3,N4,N6,G7,G16). Each item is scored on a scale of 1-7, where 1 = an absence of symptoms and 7 = extreme symptoms. The positive and negative syndrome scale total score is the sum of the scores from each domain (range = 15-105); higher scores indicate greater severity of symptoms.

Time frame:
Baseline to week 12
Reported as:
Mean · Units on a scale
Positive and Negative Syndrome Scale (PANSS) Total Scores
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Baseline67.43 ± 9.3567.92 ± 10.8671.4 ± 10.362.8 ± 6.769.6 ± 11.167.8 ± 11.1
Day 1468.38 ± 10.3769.00 ± 11.4067.3 ± 8.569.5 ± 13.567.4 ± 10.567.9 ± 13.6
Day 2866.10 ± 10.3865.44 ± 7.3067.0 ± 10.981.3 ± 4.766.8 ± 11.466.5 ± 11.1
Day 4270.09 ± 10.8865.88 ± 12.0168.3 ± 12.773.3 ± 9.861.8 ± 10.964.1 ± 12.5
Day 5666.60 ± 8.1361.14 ± 6.9164.3 ± 11.770.0 ± 7.163.2 ± 14.461.4 ± 11.7
Day 7068.50 ± 7.6559.57 ± 7.14————
Day 84 (Week 12)64.70 ± 13.9259.17 ± 6.2764.4 ± 12.274.8 ± 7.259.0 ± 11.160.9 ± 11.3
SecondaryPANSS Symptom Factor Scores

The PANSS Marder factors examine schizophrenia symptoms in five domains: positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility/excitement, and depression/anxiety. The Marder factor positive symptom score (range = 8-56) measures responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12) while the negative symptom factor score (range = 7-49) consists of 7 items (N1,N2,N3,N4,N6,G7,G16). Each item is scored on a scale of 1-7, where 1 = an absence of symptoms and 7 = extreme symptoms.

Time frame:
Baseline to week 12
Reported as:
Mean · Units on a scale
PANSS Symptom Factor Scores
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Baseline - Negative symptoms21.29 ± 4.4521.00 ± 5.2023.0 ± 4.720.6 ± 3.323.3 ± 4.723.5 ± 4.1
Day 14 - Negative symptoms22.46 ± 5.1320.40 ± 3.9522.9 ± 3.420.8 ± 2.921.8 ± 4.522.2 ± 5.3
Day 28 - Negative symptoms18.40 ± 6.6720.44 ± 3.6820.9 ± 4.820.3 ± 3.121.5 ± 4.022.1 ± 4.9
Day 42 - Negative symptoms21.09 ± 5.4519.00 ± 5.5021.3 ± 4.522.3 ± 3.221.5 ± 5.120.7 ± 5.1
Day 56 - Negative symptoms21.10 ± 5.9318.71 ± 4.7220.4 ± 4.721.8 ± 4.219.8 ± 4.920.3 ± 5.7
Day 70 - Negative symptoms21.20 ± 5.0717.71 ± 2.75————
Day 84 (Week 12) - Negative symptoms18.90 ± 5.3815.33 ± 3.0820.5 ± 5.922.5 ± 4.818.6 ± 4.419.4 ± 4.8
Baseline - Positive symptoms17.93 ± 3.9919.75 ± 3.9318.9 ± 4.618.0 ± 3.717.6 ± 4.217.2 ± 5.4
Day 14 - Positive symptoms18.23 ± 4.7521.30 ± 4.3517.8 ± 3.818.3 ± 5.318.1 ± 3.918.0 ± 5.7
Day 28 - Positive symptoms17.60 ± 4.7719.22 ± 5.1917.9 ± 4.324.3 ± 6.018.0 ± 4.917.4 ± 5.9
Day 42 - Positive symptoms17.82 ± 4.3118.75 ± 4.1318.2 ± 4.822.5 ± 6.016.0 ± 4.416.2 ± 4.7
Day 56 - Positive symptoms17.90 ± 4.9320.71 ± 1.5017.7 ± 5.020.5 ± 3.117.2 ± 6.115.8 ± 4.5
Day 70 - Positive symptoms19.20 ± 2.8619.29 ± 2.69————
Day 84 (Week 12) - Positive symptoms17.70 ± 5.2519.67 ± 3.6117.3 ± 4.521.5 ± 2.616.5 ± 4.715.5 ± 4.3
SecondaryBrief Negative Symptom Scale (BNSS) Total Scores

The BNSS is a 13-item instrument designed for clinical trials that measures the severity of the negative symptoms of schizophrenia in five domains. There are 13 items organized into 6 subscales (anhedonia, distress, asociality, avolition, blunted affect, and alogia), each rated on a 7-point scale (0-6) where 0 = absent symptoms and 6 = severe symptoms. The total score is calculated by summing the individual items (13) of each subscale and has a range of 0-78.

Time frame:
Baseline to week 12
Reported as:
Mean · Units on a scale
Brief Negative Symptom Scale (BNSS) Total Scores
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Baseline34.79 ± 14.9835.17 ± 13.6836.6 ± 14.936.4 ± 6.738.1 ± 13.738.4 ± 13.8
Day 1435.08 ± 12.4832.90 ± 13.4736.1 ± 11.429.3 ± 11.134.1 ± 12.835.2 ± 12.8
Day 2829.90 ± 14.4933.25 ± 8.9432.6 ± 12.932.7 ± 7.433.1 ± 13.436.5 ± 10.3
Day 4234.09 ± 11.9536.38 ± 14.7935.1 ± 11.335.0 ± 11.835.5 ± 12.632.7 ± 13.4
Day 5637.40 ± 18.6034.00 ± 12.1230.3 ± 12.137.5 ± 16.330.8 ± 11.832.3 ± 13.6
Day 7033.10 ± 7.2334.00 ± 15.15————
Day 84 (Week 12)30.40 ± 12.8628.17 ± 20.4432.7 ± 13.433.3 ± 10.629.6 ± 9.229.2 ± 12.4
SecondaryDefeatist Performance Attitude Scale (DPAS) Scores

The DPAS is a 15-item, patient-rated assessment that evaluates expectations of failures or self-defeating beliefs related to prior failed experiences as well as illness on a 7-point Likert scale (total range = 15-105) ranging from totally agree (1) to totally disagree (7).

Time frame:
Baseline to week 12
Reported as:
Mean · Units on a scale
Defeatist Performance Attitude Scale (DPAS) Scores
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Baseline34.73 ± 13.9230.25 ± 12.4340.2 ± 14.640.0 ± 6.438.2 ± 15.935.9 ± 16.2
Day 4240.54 ± 16.3727.50 ± 18.6537.5 ± 14.239.3 ± 9.338.8 ± 16.236.0 ± 16.2
Day 84 (Week 12)38.80 ± 13.4216.00 ± 4.9836.0 ± 15.254.3 ± 16.439.0 ± 19.932.2 ± 13.6
SecondaryNumber of Participants With Suicidal Ideation or Behavior, and Self-injurious Behavior Without Suicidal Intent on the Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a suicide risk assessment tool used to help identify the risk of suicide.

Time frame:
Baseline through Day 84
Reported as:
Number · Number of participants
Number of Participants With Suicidal Ideation or Behavior, and Self-injurious Behavior Without Suicidal Intent on the Columbia Suicide Severity Rating Scale (C-SSRS)
Number of participantsPart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Suicidal ideation or behavior001021
Self-injurious behavior without suicidal intent100000
SecondaryExtrapyramidal Symptom Rating Scale, Abbreviated (ESRS-A)

The ESRS-A is used to evaluate the presence and severity of extrapyramidal symptoms. Items are rated on a scale of 0 (no symptoms) to 5 (extreme symptoms).

Time frame:
Baseline through Day 84
Reported as:
Mean · Units on a scale
Extrapyramidal Symptom Rating Scale, Abbreviated (ESRS-A)
Units on a scalePart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Akathisia Baseline0.07 ± 0.260.08 ± 0.290.27 ± 0.870.00 ± 0.000.27 ± 0.830.38 ± 0.98
Akathisia Day 840.00 ± 0.000.00 ± 0.000.29 ± 0.940.00 ± 0.000.10 ± 0.450.10 ± 0.44
Dyskinesia Baseline0.00 ± 0.000.33 ± 0.890.46 ± 1.950.75 ± 0.960.17 ± 0.380.63 ± 1.68
Dyskinesia Day 840.10 ± 0.320.00 ± 0.000.16 ± 0.900.00 ± 0.000.15 ± 0.490.29 ± 0.72
Dystonia Baseline0.07 ± 0.260.00 ± 0.000.24 ± 0.860.00 ± 0.000.03 ± 0.180.16 ± 0.51
Dystonia Day 840.00 ± 0.000.00 ± 0.000.26 ± 1.030.00 ± 0.000.05 ± 0.220.00 ± 0.00
Parkinsonism Baseline0.13 ± 0.520.42 ± 1.001.03 ± 2.362.20 ± 1.922.00 ± 3.242.22 ± 4.15
Parkinsonism Day 840.20 ± 0.630.33 ± 0.821.03 ± 2.870.33 ± 0.581.15 ± 2.681.00 ± 2.30
SecondaryMaximum Serum Concentration (Cmax) of RO6889450
Time frame:
Day 42
Reported as:
Geometric mean · ng/mL
Maximum Serum Concentration (Cmax) of RO6889450
ng/mLPart B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Maximum Serum Concentration (Cmax) of RO6889450157 ± 58.7794 ± 40.31550 ± 43.9
SecondaryArea Under the Curve at Steady State (AUCss) of RO6889450
Time frame:
Day 42
Reported as:
Geometric mean · h*ng/mL
Area Under the Curve at Steady State (AUCss) of RO6889450
h*ng/mLPart B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Area Under the Curve at Steady State (AUCss) of RO68894502980 ± 54.815100 ± 43.828600 ± 48.4

Adverse events

Collected over Up to Day 84 (Week 12). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Monotherapy (Placebo)0/15 (0%)0/15 (0%)7/15 (46.7%)
Part A: Monotherapy (150 mg)0/12 (0%)1/12 (8.3%)4/12 (33.3%)
Part B: Add-on Therapy (Placebo)1/37 (2.7%)1/37 (2.7%)9/37 (24.3%)
Part B: Add-on Therapy (45 mg)0/5 (0%)0/5 (0%)2/5 (40%)
Part B: Add-on Therapy (150 mg)0/30 (0%)2/30 (6.7%)8/30 (26.7%)
Part B: Add-on Therapy (300 mg)0/32 (0%)0/32 (0%)4/32 (12.5%)
Most frequent serious events
Most frequent serious events
EventPart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
ConstipationGastrointestinal disorders0/151/120/370/50/300/32
Rhinovirus infectionInfections and infestations0/150/120/370/51/300/32
Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/150/120/370/51/300/32
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/150/120/370/51/300/32
Accidental deathGeneral disorders0/150/121/370/50/300/32
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPart A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)
Lip painGastrointestinal disorders0/150/120/371/50/300/32
Non-cardiac chest painGeneral disorders0/150/120/371/50/300/32
Upper respiratory tract infectionInfections and infestations2/150/120/371/50/300/32
Pain in extremityMusculoskeletal and connective tissue disorders0/150/120/371/50/300/32
Dizziness posturalNervous system disorders0/150/120/371/50/300/32
InsomniaPsychiatric disorders1/152/120/370/50/300/32
NauseaGastrointestinal disorders0/152/120/370/51/301/32
NasopharyngitisInfections and infestations0/150/122/370/53/303/32
Urinary tract infectionInfections and infestations0/151/120/370/50/300/32
ConstipationGastrointestinal disorders0/151/120/370/51/300/32

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)Total
Mean42.7 ± 9.943.3 ± 6.641.3 ± 9.741.6 ± 11.340.0 ± 9.640.9 ± 9.241.3 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)Total
Female33100111239
Male129275192092
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)Total
Hispanic or Latino10206514
Not Hispanic or Latino14113552427116
Unknown or Not Reported0100001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Monotherapy (Placebo)Part A: Monotherapy (150 mg)Part B: Add-on Therapy (Placebo)Part B: Add-on Therapy (45 mg)Part B: Add-on Therapy (150 mg)Part B: Add-on Therapy (300 mg)Total
American Indian or Alaska Native0000000
Asian10806419
Native Hawaiian or Other Pacific Islander0010001
Black or African American12911571054
White23160161855
More than one race0000101
Unknown or Not Reported0010001
08

Study locations

45 sites
  • CITrials, Inc.
    Bellflower, California 90706, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • California Clinical Trials
    Glendale, California 91206, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Catalina Research Institute LLC - MRA
    Montclair, California 91763, United States
  • CITrials, Inc.
    Riverside, California 92506, United States
  • California Neuropsychopharmacology Clinical Research Institute, LLC
    San Diego, California 92102, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Collaborative Neuroscience Network Inc.
    Torrance, California 90502, United States
  • Yale School of Medicine - CT Mental Health Center (CMHC) - Schizophrenia Research Clinic
    New Haven, Connecticut 06519, United States
  • Innovative Clinical Research, Inc.
    Lauderhill, Florida 33319, United States
  • Lifestream Behavioral Center
    Leesburg, Florida 34748, United States
  • Advanced Research Institute of Miami
    Miami, Florida 33135, United States
  • Health Synergy Clinical Research
    Okeechobee, Florida 34972, United States
  • Emory University
    Atlanta, Georgia 30329, United States
  • Northwestern University
    Chicago, Illinois 60611-2908, United States
  • CBH Health
    Gaithersburg, Maryland 20877, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • Psych Care Consultants Research
    Saint Louis, Missouri 63128, United States
  • Millennium Psychiatric Associates, LLC
    Saint Louis, Missouri 63132, United States
  • Manhattan Psychiatric Center; Psychopharmacology Research Unit
    New York, New York 10035, United States
  • JPS Health Network
    Fort Worth, Texas 76104, United States
  • Pillar Clinical Research LLC
    Garland, Texas 75042, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University Hills Clinical Research
    Irving, Texas 75062, United States
  • The Solace Center
    Missouri City, Texas 77459, United States
  • Psychiatry & Behavioral Center
    Richmond, Texas 77406, United States
  • @ Health Texas
    Richmond, Texas 77407, United States
  • Kohnodai Hp., National Center for Global Health and Medicine
    Chiba, 272-8516, Japan
  • National Hospital Organization Ryukyu Hospital
    Kunigami, 904-1201, Japan
  • National Center of Neurology and Psychiatry
    Tokyo, 187-8551, Japan
  • Seishinkai Okehazama Hospital Fujita Kokoro Care Center
    Toyoake, 470-1168, Japan
  • Hiyoshi Hospital
    Yokohama-shi, 223-0062, Japan
  • Hospital Universitario Central de Asturias
    Oviedo, Asturias 33011, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • C.H. Regional Reina Sofia - PPDS
    Cordoba, 14004, Spain
  • Hosp Univ Fundacion Alcorcon
    Madrid, 28922, Spain
  • Complejo Asistencial Universitario de Salamanca ? H. Clinico
    Salamanca, 37007, Spain
  • CNCE Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council
    Nove, Katerynoslav Governorate 25491, Ukraine
  • Communal Non-Commercial Enterprise of Kharkiv RC Regional clinical psychiatric hospital #3
    Kharkiv, Kharkiv Governorate 61068, Ukraine
  • Public NPE Kherson Regional Institution of Mental Care of Kherson RC
    Kherson, Kherson Governorate 73488, Ukraine
  • Municipal Non-Commercial Enterprise Odesa RMC for Mental Health of Odessa Regional Council
    Odesa, Kherson Governorate 65006, Ukraine
  • ME Dnipropetrovsk Regional Clinical Hospital n.a. I.I Mechnykov Dnipropetrovsk Regional Council
    Dnipro, KIEV Governorate 49005, Ukraine
  • Zakarpattia Regional Clinical Hospital n.a. Andrii Novak
    Uzhhorod, KIEV Governorate 88000, Ukraine
  • Communal NPE Vinnytsia Reg. Clin. Psychoneurolog. Hosp. n.a. O.I. Yushchenko of Vinnytsia RC
    Vinnytsia, Podolia Governorate 21037, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Mar 2023, 51 months.

Results were first posted in Aug 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2018
First posted
Sep 13, 2018
StartActual
Dec 4, 2018
Primary completionActual
Mar 12, 2023
CompletionActual
Mar 12, 2023
Results first posted
Aug 12, 2024
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03669640
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 13, 2018
Start date
Dec 4, 2018
Primary completion
Mar 12, 2023
Completion
Mar 12, 2023
Results posted
Aug 12, 2024
Last update
Aug 12, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ralmitaront

Start the discussion